Clinical Trials

257 enrolled

Hodgkin Disease, Recurrence

NCT05355051 2026-04-15

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

24 enrolled

Hodgkin Disease

NCT05922904 2026-04-15

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

25 enrolled

Phase 1 Active not recruiting

Hodgkin Disease

NCT03240211 2026-04-07

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

37 enrolled

Lymphoma, T-Cell

NCT04417166 2026-04-07

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

30 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT06242834 2026-04-01

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

32 enrolled

Lymphoma, B-Cell

NCT03983668 2026-03-30

CMP-001 for Relapsed and Refractory Lymphoma

Phase 1/2 Terminated

14 enrolled 11 charts

Phase 1 Active not recruiting

Lymphoma

NCT03361852 2026-03-25

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

20 enrolled

Lymphoma, Follicular

NCT06863402 2026-03-24

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04960618 2026-03-23

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

14 enrolled

Phase 2 Not yet recruiting

Mycosis Fungoides, Sezary Syndrome

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Hodgkin Disease

NCT02332668 2026-03-16

MK-3475-051

Phase 1/2 Recruiting

370 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Terminated

5 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Phase 1 Recruiting

15 enrolled

Lymphoma

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 3 FDA

Phase EARLY_PHASE1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

22 enrolled

DermatologicGynecologicLymphoid

Lymphoma, Neoplasms, Recurrence

NCT04752826 2026-02-18

MK-3475-D20

Phase 1/2 Recruiting

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT02362997 2026-02-12

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Phase 2 Suspended

18 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT06484920 2026-02-10

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

24 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03598608 2026-02-05

MK-4280-003

Phase 1/2 Completed

137 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

84 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05508867 2026-01-20

MK-4280A-008

Phase 2 Completed

203 enrolled